ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2620

Development Of De Novo Major Involvement During The Follow-Up In Behçet’s Disease

Claudia Ferrari1, Rosaria Talarico2, Chiara Stagnaro3, Anna d'Ascanio4, Chiara Tani3, Chiara Baldini3, Marta Mosca1 and Stefano Bombardieri3, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Rheumatology Unit, Pisa, Italy, 3University of Pisa, Rheumatology Unit, Pisa, Italy, 4Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Behçet’s disease (BD) is globally characterized by a variable spectrum of disease profile: while prevalent muco-cutaneous lesions and arthritis represent the only clinical features in patients with a benign disease subset, there are other patients who develop potentially sight or life-threatening manifestations, due to ocular, neurological or major vascular involvement. The primary aim of the study was to evaluate the incidence of the novo major involvement during the follow-up in a cohort of  patients with BD; the secondary aim was to analyze the epidemiological profile and the long-term outcome of those patients who developed de novo major involvement.

Methods:  One hundred and twenty patients were evaluated. The male/female ratio was 1.6:1, with a mean disease duration of 11±5 years. Their mean age was 42±9 years (min:18, max:77), while the mean age at disease onset was 25±4 years (min:10, max:58). The mean ± SD duration of follow-up at our centre was 8±2 (min:2, max:12) years. We have defined the development of de novo major involvement during the follow-up as the occurrence of severe ocular (anterior uveitis, posterior uveitis, retinal vasculitis), vascular (deep vein thrombosis, superficial vein thrombosis, arterial thrombosis, arterial aneurysm) or CNS (ischaemic pons-mesencephalon lesions and meningoencephalitis) involvement after a latency period from the diagnosis of at least 3 years

Results: At the time of diagnosis, the 52% of the cohort (n=62) presented a prevalent muco-cutaneous involvement. Among this sub group of patients, we observed that after at least 3 years from the diagnosis, 21 patients (34%)  was characterized by the occurrence of de novo major involvement (i.e. ocular: 3; CNS: 9; vascular: 9). The demographic profile of this subgroup (male: 19, female: 2) was characterized by a mean age of 33±4 years (min 24-max 40) and a young age at disease onset. The long term outcome after a mean follow-up of 8 years has shown that the majority of these subjects presented during the disease course also relapsing attacks. Moreover, they were characterized by a bigger number of DMARDs (both traditional and anti TNF-alpha)  compared to the other part of the cohort

Conclusion: As awaited, younger age and male sex represent predictive factors of poor long-term clinical outcome. We have found that ocular disease seems the organ involvement that more frequently has an onset before the first years of disease. Globally, he development of the novo major involvement during the course of BD represents an entity that may confirm that a tight control is strongly recommended during the course of BD


Disclosure:

C. Ferrari,
None;

R. Talarico,
None;

C. Stagnaro,
None;

A. d’Ascanio,
None;

C. Tani,
None;

C. Baldini,
None;

M. Mosca,
None;

S. Bombardieri,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-de-novo-major-involvement-during-the-follow-up-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology